trending Market Intelligence /marketintelligence/en/news-insights/trending/zbwecfyantfbirjowwsz8q2 content esgSubNav
In This List

MabVax to delist from Nasdaq

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


MabVax to delist from Nasdaq

MabVax Therapeutics Holdings Inc. said it received a delisting determination from Nasdaq Stock Market LLC.

MabVax directors previously decided against planning to regain compliance with the exchange's listing rules.

MabVax was not in compliance with the exchange's listing requirements for stockholders' equity and periodic report filings. MabVax underwent a Securities and Exchange Commission investigation regarding its financial and registration statements.

The San Diego-based biopharmaceutical company will not appeal the decision, and its common stock will be suspended from the Nasdaq Capital Market on July 11.